Oruka Therapeutics, Inc. Common Stock ORKA

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

• GlobeNewswire Inc. 23 sept

  Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

  Oruka Therapeutics reported positive Week 28 interim data from its EVERLAST-A Phase 2a trial of ORKA-001, an IL-23p19 monoclonal antibody for plaque psoriasis. The drug demonstrated deepening clinical responses with 71.4% of patients achieving PASI 100 (complete skin clearance) and 87.3% achieving PASI 90, six months after the last dose with no additional dosing beyond Week 4. The drug maintained a favorable safety profile consistent with the IL-23 class. Full 52-week data is expected in December 2026.

  

• GlobeNewswire Inc. 24 ago

  Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

  Oruka Therapeutics announced the appointment of Todd Edwards as Chief Commercial Officer effective August 24, 2026. Edwards brings over 25 years of commercial leadership experience in immunology and dermatology from previous roles at Arcutis Biotherapeutics, Incyte Corporation, UCB S.A., and AbbVie. The appointment reflects Oruka's commitment to building a commercial organization to advance its pipeline candidates ORKA-001 and ORKA-002 toward commercialization for chronic skin diseases.

  

• The Motley Fool 27 jun

  Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

  Oruka Therapeutics' Senior Vice President of Finance Arjun Agarwal sold 9,854 shares worth approximately $687,000 in mid-June 2026, reducing his direct holdings by 36.83%. The sale occurred after the stock had already surged 450% over the previous year and two weeks before it reached nearly 700% gains. The insider sale follows positive Phase 2 clinical data for the company's monoclonal antibody therapies ORKA-001 and ORKA-002, though the company continues to operate at a net loss with quarterly losses widening to $31.8 million.

  

• The Motley Fool 24 jun

  Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

  Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, sold 10,290 shares worth approximately $608,000 on May 18, 2026, at a weighted average price of $59.07 per share. The sale was part of a pre-arranged Rule 10b5-1 trading plan and should not concern investors, as it was non-discretionary. The transaction came after the stock surged 457.71% over one year, driven by encouraging clinical trial data and a $700 million public offering announced in April.